Corvus Pharmaceuticals Inc

NASDAQ:CRVS  
2.91
-0.03 (-1.02%)
Products, Regulatory

Corvus Pharmaceuticals Provides Update On Clinical Trial Of Cpi-006 For Patients With Covid-19

Published: 09/10/2020 13:43 GMT
Corvus Pharmaceuticals Inc (CRVS) - Corvus Pharmaceuticals Provides Update on Clinical Trial of Cpi-006 for Patients With Covid-19.
Corvus Pharmaceuticals Inc - Patients Treated in First Two Cohorts of Phase 1 Study for Cpi-006 Had Low Pre-treatment Titers of Antibodies.
Corvus Pharmaceuticals Inc - Additional Data From Cpi-006 Covid-19 Phase 1 Study is Expected to Be Available in Late 2020.